Vitreous Zonule in Primary Angle-Closure Glaucoma
A Cross-Sectional, Prospective Observational Study on the Role of the Vitreous Zonule in the Pathogenesis of Primary Angle-Closure Glaucoma
1 other identifier
observational
440
1 country
1
Brief Summary
This study aims to investigate the role of the vitreous zonule (VZ) in the pathogenesis of primary angle-closure glaucoma (PACG) and to explore the feasibility of three-dimensional ultrasound biomicroscopy (3D-UBM) for imaging the circumferential VZ. This prospective, observational study will enroll patients with primary angle-closure disease (PACD), including primary angle-closure suspect (PACS), primary angle-closure (PAC), and PACG, as well as healthy controls. All participants will undergo comprehensive ophthalmic examinations, including gonioscopy, biometric measurements using IOLMaster, and UBM imaging. The study consists of three main components: (1) analysis of VZ morphology, location, number of visible quadrants, and anterior segment parameters across different age groups and axial length groups in healthy individuals, with comparisons to age-matched PACD patients; (2) development and validation of a 3D-UBM imaging system using a rotational scanning approach to reconstruct the spatial structure of the VZ; and (3) characterization of VZ features, including density and morphology, in normal eyes versus PACD eyes using 3D-UBM. The primary outcomes include the presence, quadrant count, and morphological characteristics (vitreous zonule-pars plana angle and maximum distance) of the VZ, as well as anterior segment parameters such as lens vault, anterior chamber depth, trabecular-iris angle, and angle opening distance. By elucidating age-related and axial length-related changes in the VZ and establishing 3D-UBM as a novel imaging modality for the posterior zonular apparatus, this study seeks to provide new evidence for the mechanistic role of the VZ in angle-closure glaucoma and to identify potential imaging biomarkers for early diagnosis and risk stratification.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
April 5, 2026
CompletedFirst Posted
Study publicly available on registry
April 13, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
April 13, 2026
April 1, 2026
2.4 years
April 5, 2026
April 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Vitreous Zonule Visibility on Ultrasound Biomicroscopy
Presence and quadrant count of the VZ assessed by ultrasound biomicroscopy (UBM). VZ is defined as fibrous bands extending from the pars plana to the posterior lens equator or ciliary processes. Presence is defined as VZ visible in at least one quadrant; quadrant count ranges from 0 to 4.
Baseline
Study Arms (4)
Group 1 Healthy Controls
Group 2 Primary Angle-Closure Suspects (PACS)
Group 3 Primary Angle Closure
Group 4 Primary Angle Closure Glaucoma
Eligibility Criteria
The study population will be recruited from the Department of Ophthalmology at Peking University People's Hospital, a tertiary referral center in Beijing, China. Participants will include patients diagnosed with primary angle-closure disease (PACS, PAC, and PACG) and healthy controls with open angles. Patients will be identified from outpatient clinics and through routine ophthalmic examinations. Healthy controls will be recruited from volunteers undergoing routine eye examinations, as well as from hospital staff and community members. All participants will be recruited prospectively and consecutively to minimize selection bias.
You may qualify if:
- \. Age between 30 and 80 years, inclusive. 2. Diagnosis of primary angle-closure disease (PACS, PAC, or PACG) according to standardized gonioscopic criteria; or healthy controls with open angles. 3. Lens opacity graded \< 2 for cortical and nuclear opacities according to the Lens Opacities Classification System III (LOCS III). 4. Ability and willingness to provide written informed consent.
You may not qualify if:
- \. Any intraocular disease affecting the anterior or posterior segment, including but not limited to corneal disease, iris abnormalities, lens disorders other than age-related cataract, vitreous disorders, uveoretinal diseases, or optic neuropathies. 2. Prior intraocular surgery or laser treatment, including cataract surgery, trabeculectomy, laser trabeculoplasty, laser peripheral iridotomy, laser iridoplasty, or vitreoretinal surgery. 3. Systemic diseases that may affect ocular examination or confound measurements, such as end-stage cardiac disease, renal disease, pulmonary disease, or advanced malignancy. 4. Inability to undergo ultrasound biomicroscopy (UBM) examination due to inability to maintain supine position or other contraindications. 5. Pregnancy or lactation. 6. Any condition that, in the opinion of the investigator, would compromise the participant's ability to comply with study procedures or affect the validity of the study results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Peking University People's Hospital
Beijing, 100044, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 5, 2026
First Posted
April 13, 2026
Study Start
January 1, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2027
Last Updated
April 13, 2026
Record last verified: 2026-04